$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416117691 Filed on August 09, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q2
Revenue	$3.271M	$5.195M	$2.163M
YoY Change	51.23%	320.99%	86.14%
Cost Of Revenue	$2.148M	$1.036M	$1.197M
YoY Change	79.45%	14.6%	64.2%
Gross Profit	$1.123M	$4.159M	$966.0K
YoY Change	16.25%	1156.5%	123.09%
Gross Profit Margin	34.33%	80.06%	44.66%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$1.550M		$2.366M
YoY Change	-34.48%		-41.14%
% of Gross Profit	138.06%		244.95%
Depreciation & Amortization	$176.1K	$180.0K	$161.5K
YoY Change	9.04%	-357.14%	-22.89%
% of Gross Profit	15.68%	4.33%	16.71%
Operating Expenses	$2.361M	$3.588M	$3.373M
YoY Change	-30.0%	-38.01%	-30.65%
Operating Profit	-$1.238M	$571.0K	-$2.407M
YoY Change	-48.57%	-110.46%	-45.68%
Interest Expense	$68.94K		$76.23K
YoY Change	-9.56%		-2.53%
% of Operating Profit
Other Income/Expense, Net	$2.334M	$7.408M	$7.139M
YoY Change	-67.31%	-924.94%	205.35%
Pretax Income	$1.097M		$4.735M
YoY Change	-76.84%		-207.57%
Income Tax	-$3.000K	-$520.0K	$0.00
% Of Pretax Income	-0.27%		0.0%
Net Earnings	$1.099M	$8.499M	$4.732M
YoY Change	-76.78%	-233.84%	-325.98%
Net Earnings / Revenue	33.6%	163.6%	218.77%
Basic Earnings Per Share	$0.00	$0.03	$0.02
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	722.8M shares	695.2M shares	646.9M shares
Diluted Shares Outstanding	722.8M shares		812.6M shares

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.81M	$11.51M	$11.62M
YoY Change	10.24%	54.29%	42.23%
Cash & Equivalents	$12.81M	$11.51M	$11.62M
Short-Term Investments
Other Short-Term Assets	$220.0K	$380.0K	$260.0K
YoY Change	-15.38%	-2.56%	18.18%
Inventory	$3.740M	$3.294M	$2.860M
Prepaid Expenses
Receivables	$1.220M	$1.530M	$1.050M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.99M	$16.71M	$15.78M
YoY Change	14.01%	35.55%	30.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.223M	$8.111M	$6.950M
YoY Change	18.31%	26.69%	40.4%
Goodwill
YoY Change
Intangibles	$6.412M	$6.412M
YoY Change		0.47%
Long-Term Investments	$50.00K	$50.00K	$180.0K
YoY Change	-72.22%	-75.0%	800.0%
Other Assets	$437.7K	$437.7K	$600.0K
YoY Change	-27.05%	-45.7%	2.58%
Total Long-Term Assets	$15.07M	$14.96M	$14.13M
YoY Change	6.65%	10.09%	18.86%
TOTAL ASSETS
Total Short-Term Assets	$17.99M	$16.71M	$15.78M
Total Long-Term Assets	$15.07M	$14.96M	$14.13M
Total Assets	$33.06M	$31.67M	$29.91M
YoY Change	10.53%	22.2%	24.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.458M	$1.804M	$2.490M
YoY Change	-41.46%	-46.67%	-22.43%
Accrued Expenses	$1.400M	$555.4K
YoY Change		-9.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$34.68K	$410.0K
YoY Change	-100.0%		-33.87%
Long-Term Debt Due	$510.0K	$308.3K	$450.0K
YoY Change	13.33%	16.25%	-87.07%
Total Short-Term Liabilities	$4.379M	$4.640M	$4.360M
YoY Change	0.44%	-8.46%	-40.36%
LONG-TERM LIABILITIES
Long-Term Debt	$2.110M	$2.180M	$2.070M
YoY Change	1.93%	5.31%
Other Long-Term Liabilities	$41.33K	$47.42K	$15.15M
YoY Change	-99.73%	-92.46%	-85.02%
Total Long-Term Liabilities	$13.14M	$15.87M	$41.87M
YoY Change	-68.61%	-22.89%	-58.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.379M	$4.640M	$4.360M
Total Long-Term Liabilities	$13.14M	$15.87M	$41.87M
Total Liabilities	$17.52M	$20.51M	$21.58M
YoY Change	-18.8%	-20.04%	-80.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.6M	-$142.7M
YoY Change		0.48%
Common Stock	$111.0M	$109.8M
YoY Change		2.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change		0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	-$30.89M	-$33.12M	$8.330M
YoY Change
Total Liabilities & Shareholders Equity	$33.06M	$31.67M	$29.91M
YoY Change	10.53%	22.2%	24.78%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q2
OPERATING ACTIVITIES
Net Income	$1.099M	$8.499M	$4.732M
YoY Change	-76.78%	-233.84%	-325.98%
Depreciation, Depletion And Amortization	$176.1K	$180.0K	$161.5K
YoY Change	9.04%	-357.14%	-22.89%
Cash From Operating Activities	-$760.0K	$600.0K	$1.890M
YoY Change	-140.21%	-115.58%	-144.89%
INVESTING ACTIVITIES
Capital Expenditures	-$280.0K	-$570.0K	-$720.0K
YoY Change	-61.11%	-5.0%	4.35%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$280.0K	-$570.0K	-$720.0K
YoY Change	-61.11%	-5.0%	-116.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.470M		$2.041M
YoY Change	21.06%		127.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.350M	3.370M	2.980M
YoY Change	-21.14%	-7.67%	148.33%
NET CHANGE
Cash From Operating Activities	-760.0K	600.0K	1.890M
Cash From Investing Activities	-280.0K	-570.0K	-720.0K
Cash From Financing Activities	2.350M	3.370M	2.980M
Net Change In Cash	1.310M	3.400M	4.150M
YoY Change	-68.43%	-525.0%	237.4%
FREE CASH FLOW
Cash From Operating Activities	-$760.0K	$600.0K	$1.890M
Capital Expenditures	-$280.0K	-$570.0K	-$720.0K
Free Cash Flow	-$480.0K	$1.170M	$2.610M
YoY Change	-118.39%	-136.0%	-174.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	555352	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142664747	USD
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	-30892500	USD
CY2015Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1675773	USD
CY2016Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2551858	USD
CY2015Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	487332	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	-33122237	USD
CY2016Q2	us-gaap	Assets Assets	33059071	USD
CY2016Q1	us-gaap	Assets Assets	31674149	USD
CY2015Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	7214261	USD
CY2016Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	2399921	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33059071	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31674149	USD
CY2016Q2	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	7968646	USD
CY2016Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	10368567	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3278887	USD
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3025557	USD
CY2016Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	718309	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1457761	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1804429	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4379142	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4640189	USD
CY2016Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1658322	USD
CY2016Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1654777	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41331	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47422	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	730974	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	711546	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	110254090	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	109137805	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141570723	USD
CY2016Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	719288	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2163105	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	3271146	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	1196968	USD
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	2147552	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	966137	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	1123594	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2366262	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1550370	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	754444	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	699011	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	90479	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	89384	USD
CY2015Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	157915	USD
CY2016Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22392	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	3369100	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	2361157	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2402963	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1237563	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	76228	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	68943	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7138033	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2334087	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	1094024	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	4732320	USD
CY2016Q2	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-2142857	USD
CY2015Q2	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	6428571	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1096524	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4735070	USD
CY2016Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89384	USD
CY2016Q2	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	704431	USD
CY2016Q2	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	38441	USD
CY2016Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2016Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	38441	USD
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	176060	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	161460	USD
CY2016Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	457450	USD
CY2015Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	573667	USD
CY2016Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	89384	USD
CY2015Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	90479	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-310051	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-397822	USD
CY2016Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	441565	USD
CY2015Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-168789	USD
CY2016Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-161345	USD
CY2015Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-148953	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2076625	USD
CY2016Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-253330	USD
CY2015Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	4913333	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-764172	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1890838	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-284498	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-716343	USD
CY2016Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	284323	USD
CY2015Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	709706	USD
CY2016Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	175	USD
CY2015Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6637	USD
CY2016Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	708431	USD
CY2015Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1199671	USD
CY2016Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2351442	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2977962	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1302772	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4152457	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7464180	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11616637	USD
CY2016Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	48417	USD
CY2016Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3491775	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2845247	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	144690	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	222784	USD
CY2016Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	98829	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	225698	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6898916	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6726401	USD
CY2015Q1	eltp	Warrants Outstanding WarrantsOutstanding	89870034	shares
CY2016Q1	eltp	Warrants Outstanding WarrantsOutstanding	41586066	shares
CY2016Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q2	eltp	Corporate Unallocated Costs CorporateUnallocatedCosts	462125	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3109	USD
CY2016Q2	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q2	eltp	Warrants Outstanding WarrantsOutstanding	30235165	shares
CY2015Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	48283968	shares
CY2016Q2	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	11350901	shares
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
CY2016Q2	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
CY2016Q2	eltp	Common Stock Traded Percent CommonStockTradedPercent	0.3	pure
CY2016Q2	eltp	Common Stock Weighted Average Price Percent CommonStockWeightedAveragePricePercent	0.97	pure
CY2015Q2	eltp	Corporate Unallocated Costs CorporateUnallocatedCosts	370075	USD
CY2016Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	317290	USD
CY2015Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	376894	USD
CY2016Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	2399921	USD
CY2015Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	7214261	USD
CY2016Q2	dei	Document Type DocumentType	10-Q
CY2016Q2	dei	Amendment Flag AmendmentFlag	false
CY2016Q2	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
CY2016Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2016Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q2	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
CY2016Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2016Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2016Q2	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q2	dei	Trading Symbol TradingSymbol	ELTP
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	733715855	shares
CY2016Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	205822	USD
CY2016Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	205822	USD
CY2016Q2	us-gaap	Loans Payable Current LoansPayableCurrent	304756	USD
CY2016Q1	us-gaap	Loans Payable Current LoansPayableCurrent	342944	USD
CY2016Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	450001	USD
CY2016Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	520829	USD
CY2016Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	500	shares
CY2016Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	500	shares
CY2016Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100	shares
CY2016Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100	shares
CY2016Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100	shares
CY2016Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	730971084	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	730871084	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	711544352	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	711444352	shares
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2500	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2750	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1048833	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11160891	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	722783442	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	722783442	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	812605460	shares
CY2016Q1	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2016Q2	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 10. COMMITMENTS AND CONTINGENCIES</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business.  The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated.  If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements.  Contingencies are inherently unpredictable and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Legal Proceedings</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Arbitration with Precision Dose, Inc.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 9, 2014, Precision Dose Inc., the parent company of TAGI Pharmaceuticals, Inc., commenced an arbitration against the Company alleging that the Company failed to properly supply, price and satisfy gross profit minimums regarding Phentermine 37.5mg tablets, as required by the parties’ agreements. Elite denied Precision Dose’s allegations and has counterclaimed that Precision Dose is no longer entitled to exclusivity rights with respect to Phentermine 37.5mg tablets, and is responsible for certain costs, expenses, price increases and lost profits relating to Phentermine 37.5mg tablets and the parties’ agreements. The parties have reached agreement in settlement of these issues, with Precision Dose agreeing to pay certain amounts to the Company in exchange for Elite agreeing to restore exclusivity rights with respect to Phentermine 37.5mg tablets, subject to certain defined conditions. Both parties have been complying with the agreed settlement terms and the Company has notified the Arbitrator of this settlement, requesting the issuance of proceeding termination documents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Due to the agreements reached and adhered to with regards to this issue, the Company has determined that no contingency loss needs to be recorded.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Operating Leases 135 Ludlow Ave.</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The 135 Ludlow Ave. lease is for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000</font> square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000</font> square feet of floor space in the building (“135 Ludlow Ave. modified lease”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. modified lease, includes an initial term, which expires on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company’s manufacturing resources are in progress.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the three month ended June 30, 2016 and 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,213</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,214</font>, respectively and recorded in general and administrative expense in the audited condensed consolidated statements of operations. Deferred</font>  <font style="FONT-FAMILY:Times New Roman, Times, Serif">rent as of June 30, 2016 and March 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,015</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,528</font>, respectively and recorded as a component of other long-term liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, <i>Asset Retirement and Environmental Obligations Asset Retirement Obligations</i>. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of June 30, 2016 and March 31, 2016, the Company had a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,316</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,895</font>, respectively and recorded as a component of other long-term liabilities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8222527	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8110721	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6411974	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6411799	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	388959	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	388959	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	437673	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	437673	USD
CY2016Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13143857	USD
CY2016Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15870482	USD
CY2016Q2	us-gaap	Liabilities Liabilities	17522999	USD
CY2016Q1	us-gaap	Liabilities Liabilities	20510671	USD
CY2016Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	46428572	USD
CY2016Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	44285715	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6898916	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6726401	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q2	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	-6087	USD
CY2015Q2	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	-5099	USD
CY2016Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	109018	USD
CY2015Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	90938	USD
CY2016Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-718309	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2015Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-171362	USD
CY2016Q2	us-gaap	Interest Paid InterestPaid	31422	USD
CY2015Q2	us-gaap	Interest Paid InterestPaid	22552	USD
CY2016Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	38441	USD
CY2015Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	849897	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2470338	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2040591	USD
CY2016Q2	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
CY2015Q2	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	13642832	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1048833	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2481941	USD
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	165753917	shares
CY2015	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	5000000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15121443	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14837122	USD
CY2016Q2	us-gaap	Depreciation Depreciation	172515	USD
CY2015Q2	us-gaap	Depreciation Depreciation	157915	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7609667	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7569667	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2016Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4453001	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2016Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.10
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.54
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	904409	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	975699	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	683411	USD
CY2016Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2016Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2470338	USD
CY2016Q2	eltp	Stock Issued During Period Value Payment Of Employee Salaries StockIssuedDuringPeriodValuePaymentOfEmployeeSalaries	10417	USD
CY2016Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	419167	USD
CY2016Q2	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.33
CY2016Q1	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.31
CY2016Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2065000	USD
CY2016Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2065000	USD
CY2016Q2	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	354453	USD
CY2016Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	354453	USD
CY2016Q2	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	153597	USD
CY2016Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	150052	USD
CY2016Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	200856	USD
CY2016Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	204401	USD
CY2016Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	21151	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	21641	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	4038890	USD
CY2016Q2	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	2399921	USD
CY2016Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6381774	USD
CY2016	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	30025	USD
CY2016	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
CY2016Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6411799	USD
CY2016Q2	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	175	USD

Files In Submission

Name	View Source	Status
0001144204-16-117691-index-headers.html	Edgar Link	pending
0001144204-16-117691-index.html	Edgar Link	pending
0001144204-16-117691.txt	Edgar Link	pending
0001144204-16-117691-xbrl.zip	Edgar Link	pending
eltp-20160630.xml	Edgar Link	completed
eltp-20160630.xsd	Edgar Link	pending
eltp-20160630_cal.xml	Edgar Link	unprocessable
eltp-20160630_def.xml	Edgar Link	unprocessable
eltp-20160630_lab.xml	Edgar Link	unprocessable
eltp-20160630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v445715_10q.htm	Edgar Link	pending
v445715_ex31-1.htm	Edgar Link	pending
v445715_ex31-2.htm	Edgar Link	pending
v445715_ex32-1.htm	Edgar Link	pending
v445715_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q2 Form 10-Q Financial Statement

#000114420416117691 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q2 Form 10-Q Financial Statement

#000114420416117691 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp